专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120004720A1 G-TYPE PEPTIDES AND OTHER AGENTS TO AMELIORATE ATHEROSCLEROSIS AND OTHER PATHOLOGIES 审中-公开
标题翻译： G型胶原蛋白和其他代谢物治疗ATHEROSCLEROSIS和其他病理学
公开(公告)号：US20120004720A1
公开(公告)日：2012-01-05
申请号：US13156269
申请日：2011-06-08
申请人： Alan M. Fogelman , Mohamad Navab , Gattadahalli M. Anantharamaiah
发明人： Alan M. Fogelman , Mohamad Navab , Gattadahalli M. Anantharamaiah
IPC分类号： A61F2/82 , C07K5/087 , C07K5/107 , A61P9/10 , A61K38/10 , A61P3/10 , A61P7/00 , C07K7/06 , C07K7/08
CPC分类号： C07K14/775 , A61K38/00 , C07K5/0808 , C07K5/0812 , C07K5/0815 , C07K5/0819 , C07K5/0821 , C07K5/101 , C07K5/1016 , C07K5/1019 , C07K5/1024
摘要： This invention provides novel peptides, and other agents, that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The peptides are highly stable and readily administered via an oral route.
摘要翻译：本发明提供了改善一种或多种动脉粥样硬化症状和/或以炎症反应为特征的其它病症的新型肽和其它药剂。在某些实施方案中，肽类似于载脂蛋白J的G *两亲性螺旋。肽是高度稳定的并且通过口服途径容易地施用。

2. 发明申请

US20080096814A1 ORALLY ADMINISTERED PEPTIDES SYNERGIZE STATIN ACTIVITY 审中-公开
标题翻译： ORALLY ADMINISTERED PEPTIDES SYNERGIZE STATIN活动
公开(公告)号：US20080096814A1
公开(公告)日：2008-04-24
申请号：US11830664
申请日：2007-07-30
申请人： Alan Fogelman , Gattadahalli Anantharamaiah , Mohamad Navab
发明人： Alan Fogelman , Gattadahalli Anantharamaiah , Mohamad Navab
IPC分类号： A61K38/04 , A61K38/16 , A61P19/10 , A61P9/10 , C07K14/00 , C07K7/00
CPC分类号： C07K7/08 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/47 , A61K31/505 , A61K38/10 , A61K38/16 , C07K14/001 , C07K14/775 , Y02P20/55 , A61K2300/00
摘要： This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.
摘要翻译：本发明提供改善一种或多种动脉粥样硬化症状的新型肽。肽通过口服途径高度稳定并容易地施用。这些肽有效地刺激pre-β高密度脂蛋白样颗粒的形成和循环和/或促进脂质运输和解毒。本发明还提供了一种跟踪哺乳动物中的肽的方法。此外，肽抑制骨质疏松症。当与他汀类药物一起使用时，肽增强了他汀类药物的活性，允许以显着较低的剂量使用他汀类药物，和/或使得他汀类药物在任何给定剂量下显着更具抗炎作用。

3. 发明授权

US07199102B2 Orally administered peptides synergize statin activity 失效
标题翻译：口服施用的肽协同他汀类活性
公开(公告)号：US07199102B2
公开(公告)日：2007-04-03
申请号：US10423830
申请日：2003-04-25
申请人： Alan M Fogelman , Gattadahalli M Anantharamaiah , Mohamad Navab
发明人： Alan M Fogelman , Gattadahalli M Anantharamaiah , Mohamad Navab
IPC分类号： A61K38/10 , A61K38/16 , C07K7/08 , C07K14/00
CPC分类号： C07K7/08 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/47 , A61K31/505 , A61K38/10 , A61K38/16 , C07K14/001 , C07K14/775 , Y02P20/55 , A61K2300/00
摘要： This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides typically range in length up to about 30 amino acids, comprise at least one class A amphipathic helix, and protect a phospholipid against oxidation by an oxidizing agent. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.
摘要翻译：本发明提供改善一种或多种动脉粥样硬化症状的新型肽。肽的长度通常在多达约30个氨基酸的范围内，包含至少一个A类两亲性螺旋，并保护磷脂免受氧化剂的氧化。肽通过口服途径高度稳定并容易地施用。这些肽有效地刺激pre-β高密度脂蛋白样颗粒的形成和循环和/或促进脂质运输和解毒。此外，肽抑制骨质疏松症。当与他汀类药物一起使用时，肽增强了他汀类药物的活性，允许以显着较低的剂量使用他汀类药物，和/或使得他汀类药物在任何给定剂量下显着更具抗炎作用。

4. 发明申请

US20070060527A1 Orally administered small peptides synergize statin activity 审中-公开
标题翻译：口服施用的小肽协同他汀类药物的活性
公开(公告)号：US20070060527A1
公开(公告)日：2007-03-15
申请号：US11485620
申请日：2006-07-11
申请人： Alan Fogelman , Gattadahalli Anantharamaiah , Mohamad Navab
发明人： Alan Fogelman , Gattadahalli Anantharamaiah , Mohamad Navab
IPC分类号： A61K38/06 , A61K38/05 , C07K5/06
CPC分类号： A61K31/47 , A61K31/366 , A61K31/405 , A61K31/44 , A61K31/505 , A61K38/03 , A61K45/06 , C07K5/0808 , C07K5/0812 , C07K5/0815 , C07K5/101 , C07K5/1016 , C07K5/1019 , C07K5/1021 , C07K7/02 , C07K7/06 , C07K14/775 , Y02P20/55 , A61K2300/00
摘要： This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.
摘要翻译：本发明提供改善一种或多种动脉粥样硬化症状的新型肽。肽通过口服途径高度稳定并容易地施用。这些肽有效地刺激pre-β高密度脂蛋白样颗粒的形成和循环和/或促进脂质运输和解毒。本发明还提供了一种跟踪哺乳动物中的肽的方法。此外，肽抑制骨质疏松症。当与他汀类药物一起使用时，肽增强了他汀类药物的活性，允许以显着较低的剂量使用他汀类药物，和/或使他汀类药物在任何给定剂量下显着更具抗炎作用。

5. 发明申请

US20060258839A1 G-type peptides to ameliorate atherosclerosis 有权
公开(公告)号：US20060258839A1
公开(公告)日：2006-11-16
申请号：US10520207
申请日：2003-04-01
申请人： Alan Fogelman , Mohamad Navab
发明人： Alan Fogelman , Mohamad Navab
IPC分类号： C07K14/47 , C07K7/08 , C07K14/775
CPC分类号： C07K14/775 , A61K38/00
摘要： This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The peptides are highly stable and readily administered via an oral route.

6. 发明申请

US20090163408A1 SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES 有权
标题翻译： SALICYLANILIDES加强口服治疗药物的口服
公开(公告)号：US20090163408A1
公开(公告)日：2009-06-25
申请号：US11835338
申请日：2007-08-07
申请人： Alan M. Fogelman , Mohamad Navab
发明人： Alan M. Fogelman , Mohamad Navab
IPC分类号： A61K38/16 , A61K38/02 , A61K38/03 , A61K47/00 , A61K38/08 , A61K38/10
CPC分类号： A61K31/165 , A61K38/03 , A61K38/04 , A61K38/16 , A61K38/17 , A61K2300/00
摘要： This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and/or niclosamide analogues when orally administered in conjunction with a peptide pharmaceutical (e.g., a class A amphipathic helical peptide as described herein) significantly increases the bioavailability of that peptide. Methods of peptide delivery using such “delivery agents” and pharmaceutical formulations are provided.
摘要翻译：本发明涉及惊人的发现，当与肽药物（例如本文所述的A类两亲螺旋肽）口服给药时，水杨酰胺和/或氯硝柳胺类似物显着增加该肽的生物利用度。提供使用这种“递送剂”和药物制剂的肽递送方法。

7. 发明申请

US20080096815A1 ORALLY ADMINISTERED PEPTIDES SYNERGIZE STATIN ACTIVITY 有权
公开(公告)号：US20080096815A1
公开(公告)日：2008-04-24
申请号：US11830675
申请日：2007-07-30
申请人： Alan Fogelman , Gattadahalli Anantharamaiah , Mohamad Navab
发明人： Alan Fogelman , Gattadahalli Anantharamaiah , Mohamad Navab
IPC分类号： A61K38/16 , A61K38/08 , A61P9/10 , C07K7/00 , C07K14/00 , A61K38/10
CPC分类号： C07K7/08 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/47 , A61K31/505 , A61K38/10 , A61K38/16 , C07K14/001 , C07K14/775 , Y02P20/55 , A61K2300/00
摘要： This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.

8. 发明授权

US07166578B2 Orally administered peptides synergize statin activity 失效
标题翻译：口服施用的肽协同他汀类活性
公开(公告)号：US07166578B2
公开(公告)日：2007-01-23
申请号：US10273386
申请日：2002-10-16
申请人： Alan M Fogelman , Gattadahalli M Anantharamaiah , Mohamad Navab
发明人： Alan M Fogelman , Gattadahalli M Anantharamaiah , Mohamad Navab
IPC分类号： A61K38/10 , A61K38/16
CPC分类号： C07K14/775 , A61K38/00
摘要： This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages. In certain embodiments, the peptides range in length from about 10 up to about 30 amino acids, comprise at least one class A amphipathic helix, and protect a phospholipid against oxidation by an oxidizing agent.
摘要翻译：本发明提供改善一种或多种动脉粥样硬化症状的新型肽。肽通过口服途径高度稳定并容易地施用。此外，肽抑制骨质疏松症。当与他汀类药物一起使用时，肽增强了他汀类药物的活性，允许以显着降低的剂量使用他汀类药物。在某些实施方案中，肽的长度范围为约10至约30个氨基酸，包含至少一个A类两亲性螺旋，并保护磷脂免受氧化剂的氧化。

9. 发明申请

US20050272162A1 Functional assay of high-density lipoprotein 失效
标题翻译：高密度脂蛋白的功能测定
公开(公告)号：US20050272162A1
公开(公告)日：2005-12-08
申请号：US11053123
申请日：2005-02-07
申请人： Alan Fogelman , Mohamad Navab , Susan Hama
发明人： Alan Fogelman , Mohamad Navab , Susan Hama
IPC分类号： G01N33/92
CPC分类号： G01N33/92 , G01N2800/044 , Y10T436/24
摘要： This invention provides novel assays that are prognostic and/or diagnostic for atherosclerosis or risk of atherosclerosis. It was discovered that high density lipoprotein (HDL) or components thereof can prevent the oxidation of lipids (e.g., lipids present in LDLs) and can also repair (reduce) already oxidized lipids and thereby reduce the inflammatory response associated with and characteristic of atherosclerotic plaque formation. Moreover it was a discovery of this invention that individuals vary in the ability of their HDL to afford such protection. Thus an assay of HDL protective and/or repair activity provides a highly effective assay for risk of atherosclerosis and its associated pathologies and such assays are provided herein.
摘要翻译：本发明提供对动脉粥样硬化或动脉粥样硬化风险的预后和/或诊断的新型测定。已经发现，高密度脂蛋白（HDL）或其组分可以防止脂质（例如LDL中存在的脂质）的氧化，并且还可以修复（减少）已经氧化的脂质，从而减少与动脉粥样硬化斑块相关的特征和炎症反应形成。此外，本发明的发现是，个体HDL提供这种保护的能力各不相同。因此，HDL保护和/或修复活性的测定提供了对动脉粥样硬化及其相关病理学的风险的高效测定，并且本文提供了此类测定。

10. 发明申请

US20050187141A1 Control of gene induced by oxidated lipids in human artery wall cells 审中-公开
标题翻译：控制人动脉壁细胞中氧化脂质诱导的基因
公开(公告)号：US20050187141A1
公开(公告)日：2005-08-25
申请号：US11028449
申请日：2005-01-03
申请人： Alan Fogelman , Mohamad Navab
发明人： Alan Fogelman , Mohamad Navab
IPC分类号： A61K48/00 , C12Q1/42 , G01N33/573 , G01N33/92 , A61K38/17
CPC分类号： C12Q1/42 , A61K48/00 , G01N33/573 , G01N33/92 , G01N2500/10 , G01N2800/323
摘要： This invention provides novel methods of inhibiting one or more symptoms of atherosclerosis. Also provided are assays for compounds that will inhibit the progression and/or ameliorate one or more symptoms of atherosclerosis. The methods and assays are based, in part, on the discovery that oxidized LDL or components thereof induce strong upregulation of MAP kinase phosphatase-1 which, in turn, is associated with an “inflammatory response” characteristic of atherosclerotic plaque formation. Inhibition of MKP-1 inhibits one or more symptoms of this response, e.g. monocyte adhesion, monocyte chemotaxis, differentiation into macrophages, etc. Inhibition of MKP-1 thus provides an effective method of inhibiting symptoms of atherosclerosis.
摘要翻译：本发明提供抑制一种或多种动脉粥样硬化症状的新方法。还提供了将抑制进展和/或改善动脉粥样硬化的一种或多种症状的化合物的测定。方法和测定部分地基于氧化的LDL或其组分诱导MAP激酶磷酸酶-1的强烈上调的发现，其又与动脉粥样硬化斑块形成特征的“炎症反应”相关。抑制MKP-1抑制这种反应的一个或多个症状，例如，单核细胞粘附，单核细胞趋化性，分化成巨噬细胞等。因此，MKP-1的抑制提供了抑制动脉粥样硬化症状的有效方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式